John T., Majem M., Legg D., Goldman J.. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. Targeted Oncology. 2023; 18(1)DOI:10.1007/s11523-022-00927-5. PMID:36534268. IF:4.400(Q2/3D).

Blakely C.M., Weder W., Bubendorf L., He J., Majem M., Shyr Y., Chaft J.E.. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. LUNG CANCER. 2023; 177DOI:10.1016/j.lungcan.2023.01.002. PMID:36736076. IF:4.500(Q1/2D).

Vidal J., Fernández-Rodríguez M.C., Casadevall D., García-Alfonso P., Páez D., Guix M., Alonso V., Cano M.T., Santos C., Durán G., Elez E., Manzano J.L., Garcia-Carbonero R., Ferreiro R., Losa F., Pineda E., Sastre J., Rivera F., Bellosillo B., Tabernero J., Aranda E., Salazar R., Montagut C.. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. CLINICAL CANCER RESEARCH. 2023; 29(2)DOI:10.1158/1078-0432.CCR-22-1696. PMID:36074154. IF:10.400(Q1/1D).

Martinez D.A.S., Quilez-Cutillas A., Jimenez-Labaig P., Sesma A., Tarazona N., Pacheco-Barcia V., Obispo B., Paez D., Quintanar T., Sanchez-Canovas M., Montes A.F., Felip E., Rodriguez-Lescure A., Elez E.. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section. Clinical & Translational Oncology. 2023; 25(3)DOI:10.1007/s12094-022-02989-3. PMID:36418642. IF:2.800(Q2/5D).

Chmielecki J., Gray J.E., Cheng Y., Ohe Y., Imamura F., Cho B.C., Lin M.-C., Majem M., Shah R., Rukazenkov Y., Todd A., Markovets A., Barrett J.C., Hartmaier R.J., Ramalingam S.S.. Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (Nature Communications, (2023), 14, 1, (1070), 10.1038/s41467-023-35961-y). Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-38999-0. PMID:37263992. IF:14.700(Q1/1D).

Bertran-Alamillo J., Giménez-Capitán A., Román R., Talbot S., Whiteley R., Floc’h N., Martínez-Pérez E., Martin M.J., Smith P.D., Sullivan I., Terp M.G., Saeh J., Marino-Buslje C., Fabbri G., Guo G., Xu M., Tornador C., Aguilar-Hernández A., Reguart N., Ditzel H.J., Martínez-Bueno A., Nabau-Moretó N., Gascó A., Rosell R., Pease J.E., Polanska U.M., Travers J., Urosevic J., Molina-Vila M.A.. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors. Molecular Cancer. 2023; 22(1)DOI:10.1186/s12943-023-01815-w. PMID:37443114. IF:27.700(Q1/1D).

Karachaliou N., Codony-Servat J., Teixidó C., Pilotto S., Drozdowskyj A., Codony-Servat C., Giménez-Capitán A., Molina-Vila M.A., Bertrán-Alamillo J., Gervais R., Massuti B., Morán T., Majem M., Felip E., Carcereny E., García-Campelo R., Viteri S., González-Cao M., Morales-Espinosa D., Verlicchi A., Crisetti E., Chaib I., Santarpia M., Luis Ramírez J., Bosch-Barrera J., Felipe Cardona A., de Marinis F., López-Vivanco G., Miguel Sánchez J., Vergnenegre A., Sánchez Hernández J.J., Sperduti I., Bria E., Rosell R.. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499). Scientific Reports. 2023; 13(1)DOI:10.1038/s41598-023-30374-9. PMID:36869103. IF:3.800(Q1/2D).

De Castro J., Insa A., Collado-Borrell R., Escudero-Vilaplana V., Martínez A., Fernandez E., Sullivan I., Arrabal N., Carcedo D., Manzaneque A.. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulmonary Medicine. 2023; 23(1)DOI:10.1186/s12890-023-02356-0. PMID:36809990. IF:2.600(Q2/5D).

Manzano J.L., Martin-Liberal J., Fernández-Morales L.A., Benítez G., Medina Martínez J., Quindós M., García-Castaño A., Fernández O., Simo R.V., Majem M., Bellido L., Ayala de Miguel P., Campos B., Espinosa E., Macías Cerrolaza J.A., Gil-Arnaiz I., Lorente D., Rodriguez-Lescure A., Perez V.N., López Castro R., Gramaje M.G., Puértolas T., Rodriguez Moreno J.F., Espasa Font L., Belaustegui Ferrández G., Cerezuela-Fuentes P.. Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study. MELANOMA RESEARCH. 2023; 33(5)DOI:10.1097/CMR.0000000000000888. PMID:36988401. IF:1.500(Q3/7D).

Provencio M., Estival A., Franco F., López-Vivanco G., Saigí M., Arasanz H., Diz P., Carcereny E., García J., Aguado C., Mosquera J., Iruarrizaga E., Majem M., Bosch-Barrera J., Mielgo-Rubio X., Guirado M., Juan-Vidal Ó., Blasco A., Lucía Gozálvez C., Del Barrio A., De Portugal T., López-Martín A., Serrano G., Campos B., Rubio J., Catot S., Esteban B., Martí-Ciriquian J.L., del Barco E., Calvo V.. Immunogenicity of COVID-19 vaccines in lung cancer patients. LUNG CANCER. 2023; 184DOI:10.1016/j.lungcan.2023.107323. PMID:37639820. IF:4.500(Q1/2D).

O'Donnell P.H., Milowsky M.I., Petrylak D.P., Hoimes C.J., Flaig T.W., Mar N., Moon H.H., Friedlander T.W., McKay R.R., Bilen M.A., Srinivas S., Burgess E.F., Ramamurthy C., George S., Geynisman D.M., Bracarda S., Borchiellini D., Geoffrois L., Maroto Rey J.P., Ferrario C., Carret A.-S., Yu Y., Guseva M., Homet Moreno B., Rosenberg J.E.. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(25)DOI:10.1200/JCO.22.02887. PMID:37369081. IF:42.100(Q1/1D).

Blanco R., Dómine M., González J.L., Loutfi S., Alfaro J., Saldaña J., Rubio J., Campos B., Hidalgo J., Barba A., Márquez D., Martin M., Olaverri A., Nadal E.. Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. LUNG CANCER. 2023; 183DOI:10.1016/j.lungcan.2023.107318. PMID:37557022. IF:4.500(Q1/2D).

John T., Grohé C., Goldman J.W., Shepherd F.A., de Marinis F., Kato T., Wang Q., Su W.-C., Choi J.H., Sriuranpong V., Melotti B., Fidler M.J., Chen J., Albayaty M., Stachowiak M., Taggart S., Wu Y.-L., Tsuboi M., Herbst R.S., Majem M.. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. Journal of Thoracic Oncology. 2023; 18(9)DOI:10.1016/j.jtho.2023.05.015. PMID:37236398. IF:21.100(Q1/1D).

Tsutani Y., Goldman J.W., Dacic S., Yatabe Y., Majem M., Huang X., Chen A., van der Gronde T., He J.. Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2. Clinical Lung Cancer. 2023; 24(4)DOI:10.1016/j.cllc.2023.02.002. PMID:36872181. IF:3.300(Q2/4D).

Herbst R.S., Wu Y.-L., John T., Grohe C., Majem M., Wang J., Kato T., Goldman J.W., Laktionov K., Kim S.-W., Yu C.-J., Vu H.V., Lu S., Lee K.Y., Mukhametshina G., Akewanlop C., De Marinis F., Bonanno L., Domine M., Shepherd F.A., Urban D., Huang X., Bolanos A., Stachowiak M., Tsuboi M.. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(10)DOI:10.1200/JCO.22.02186. PMID:36720083. IF:42.100(Q1/1D).

Provencio M., Ortega A.L., Coves-Sarto J., Calvo V., Marsé-Fabregat R., Dómine M., Guirado M., Carcereny E., Fernández N., Álvarez R., Blanco R., León-Mateos L., Sánchez-Torres J.M., Sullivan I.G., Cobo M., Sánchez-Hernández A., Massuti B., Sierra-Rodero B., Mártinez-Toledo C., Serna-Blasco R., Romero A., Cruz-Bermúdez A.. Atezolizumab Plus Bevacizumab as First-line Treatment for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer with High Tumor Mutation Burden: A Nonrandomized Controlled Trial. JAMA Oncology. 2023; 9(3)DOI:10.1001/jamaoncol.2022.5959. PMID:36520426. IF:22.300(Q1/1D).

Grünwald V., Powles T., Eto M., Kopyltsov E., Rha S.Y., Porta C., Motzer R., Hutson T.E., Méndez-Vidal M.J., Hong S.-H., Winquist E., Goh J.C., Maroto P., Buchler T., Takagi T., Burgents J.E., Perini R., He C., Okpara C.E., McKenzie J., Choueiri T.K.. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Frontiers in Oncology. 2023; 13DOI:10.3389/fonc.2023.1223282. PMID:37664025. IF:3.500(Q2/4D).

Fiala O., Buti S., Takeshita H., Okada Y., Massari F., Palacios G.A., Dionese M., Scagliarini S., Büttner T., Fornarini G., Myint Z.W., Galli L., Souza V.C., Pichler R., De Giorgi U., Quiroga M.N.G., Gilbert D., Popovic L., Grande E., Mammone G., Berardi R., Crabb S.J., Molina-Cerrillo J., Freitas M., Luz M., Iacovelli R., Calabrò F., Tural D., Atzori F., Küronya Z., Chiari R., Campos S., Caffo O., Fay A.P., Kucharz J., Zucali P.A., Rinck J.A., Zeppellini A., Bastos D.A., Aurilio G., Mota A., Trindade K., Ortega C., Sade J.P., Rizzo M., Vau N., Giannatempo P., Barillas A., Monteiro F.S.M., Dauster B., Cattrini C., Nogueira L., de Carvalho Fernandes R., Seront E., Aceituno L.G., Grillone F., Cutuli H.J., Fernandez M., Bassanelli M., Roviello G., Abahssain H., Procopio G., Milella M., Kopecky J., Martignetti A., Messina C., Caitano M., Inman E., Kanesvaran R., Herchenhorn D., Santini D., Manneh R., Bisonni R., Zakopoulou R., Mosca A., Morelli F., Maluf F., Soares A., Nunes F., Pinto A., Zgura A., Incorvaia L., Ansari J., Zabalza I.O., Landmesser J., Rizzo A., Mollica V., Sorgentoni G., Battelli N., Porta C., Bellmunt J., Santoni M.. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023; 72(11)DOI:10.1007/s00262-023-03518-z. PMID:37676282. IF:4.600(Q1/3D).

Wakelee H., Liberman M., Kato T., Tsuboi M., Lee S.-H., Gao S., Chen K.-N., Dooms C., Majem M., Eigendorff E., Martinengo G.L., Bylicki O., Rodríguez-Abreu D., Chaft J.E., Novello S., Yang J., Keller S.M., Samkari A., Spicer J.D.. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2023; 389(6)DOI:10.1056/NEJMoa2302983. PMID:37272513. IF:96.300(Q1/1D).

Tibau A., Martínez M.T., Ramos M., De La Cruz-Merino L., Santaballa A., O’Connor M., Martínez-Jañez N., Moreno F., Fernández I., Virizuela J.A., Alarcón J., de La Haba-Rodríguez J., Sánchez-Rovira P., Albacar C.R., Bueno Muiño C., Kelly C., Casas M., Bezares S., Rosell L., Albanell J.. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Therapeutic Advances in Medical Oncology. 2023; 15DOI:10.1177/17588359221148921. PMID:36743520. IF:4.300(Q2/3D).